It has been previously shown that expression of a constitutively active TGFβ type I receptor (ALK5-TD) inhibits leukemic proliferation of MDS/AML cells with concurrent ASXL1 and SETBP1 mutations. Here, ASXL1 is linked to myelodysplastic syndrome.